Key findings

  • Twopremenopausal women with unilateral granulomatous mastitis, both with local pain, inflammatory signs, abscess formation and fistulization
  • BIRADS 4Bbreast MRI in case 2 raised suspicion of malignancy; a new core biopsy showed an active chronic inflammatory process with no evidence of malignancy
  • 15 mg weeklymethotrexate added in case 1 after antibiotics, drainage and prednisone; she is currently in remission
  • 150 mg/dayazathioprine started in case 2 after a poor response to corticosteroids, later joined by methotrexate; no recurrence a year and a half after completing treatment

Abstract

Granulomatous mastitis is a rare, chronic, non-puerperal inflammatory disease of the breast characterized by heterogeneous clinical and radiological presentations, which makes diagnosis and management challenging. Its etiology remains uncertain, involving possible infectious (notably Corynebacterium spp.) and autoimmune mechanisms. Differentiation from inflammatory breast cancer is critical.

We present two cases of premenopausal women with unilateral granulomatous mastitis. Both exhibited local pain, inflammatory signs, abscess formation, and fistulization. Comprehensive clinical, imaging, and histopathological evaluations were performed. Imaging findings were variable and non-specific, and all bacteriological cultures were negative. Definitive diagnosis was established by histopathology after malignancy and infectious causes were excluded. Both patients showed limited response to antibiotics and corticosteroids, but achieved clinical remission with immunosuppressive agents (methotrexate and azathioprine).

These cases underscore the need for a multidisciplinary and individualized approach to granulomatous mastitis. While imaging is valuable for assessing extent and guiding procedures, biopsy remains essential for diagnosis. Early clinical suspicion and targeted microbiological studies can help guide therapy. Immunosuppressive treatment may reduce chronicity, recurrence, and sequelae. Long-term follow-up is recommended due to the high recurrence rate.

Introduction

Granulomatous mastitis belongs to the group of non-puerperal inflammatory diseases of the mammary gland, with a tendency toward chronicity. Its reported incidence is variable, estimated at 2.4 cases per 100,000 women per year.1–3

Mastitis can be classified in various ways: according to the period of presentation into puerperal and non-puerperal; according to its evolution into acute and chronic; according to its etiology into infectious and non-infectious; and finally, according to its etiopathogenesis.4–7

Furthermore, a distinction can be made between mastitis and paramastitis, with the former affecting the mammary glandular parenchyma and the latter affecting the supporting tissues of the breast.6,7

Mastitis can be simple or complicated, depending on the presence or absence of abscesses, which correspond to newly formed cavities with purulent secretion; these, in turn, may or may not be fistulized.6,7

The pathophysiology of puerperal mastitis begins with milk stasis and increased intraductal pressure, which causes dilation of the galactophorous ducts and vascular compression, resulting in decreased local perfusion. Retained milk provides a favorable environment for bacterial proliferation within the ducts, while nipple lesions from sucking act as a portal of entry for microorganisms. As a result, a breast infection develops, with Staphylococcus aureus being the most common causative agent.6,7

Regarding non-puerperal infectious mastitis, specific forms include tuberculous, syphilitic, and fungal mastitis. Tuberculous mastitis accounts for less than 0.1% of extrapulmonary manifestations of Mycobacterium tuberculosis. It usually occurs in young, multiparous, and lactating women, related to ductal dilation and increased vascularization of the gland. It presents a diagnostic challenge due to its close immunological and clinical similarity to other breast pathologies, as well as the possible absence of constitutional symptoms or signs pointing to other tuberculosis foci.8,9

Syphilitic mastitis is a rare extragenital manifestation of syphilis. It is caused by Treponema pallidum, mimics acute mastitis, and is often accompanied by concomitant skin lesions, although their absence does not rule out the diagnosis.10,11

As for fungal mastitis, its most common etiological agent is Candida spp., particularly Candida albicans. It is a rare condition, associated with the lactation period, and should be considered in the presence of acute mastitis.12 However, it remains controversial, since the isolation of Candida in breast milk or the areola-nipple complex does not necessarily imply infection.12,13 Other deep mycoses, such as cryptococcosis, blastomycosis, and histoplasmosis, are exceptional causes of breast involvement.14

Among the non-infectious mastitis, inflammatory breast diseases associated with the ducts (SEIMAC) stand out, including ductal and periductal mastitis.15 Their pathophysiology is based on chronic inflammation of the galactophorous ducts, leading to squamous metaplasia of the ductal epithelium, luminal obstruction by keratin plugs, stasis, and accumulation of debris. Subsequent ductal rupture causes extravasation of intraductal contents into the surrounding stroma, triggering a local inflammatory response that may be complicated by bacterial superinfection.15,16 The most frequently isolated microorganism is Staphylococcus aureus.6,7

Another diagnosis to consider is diabetic mastopathy, a rare entity with an etiopathogenesis not yet fully understood, probably related to autoimmune mechanisms.17 Histologically, it is characterized by dense, keloid-like stromal fibrosis, lobular atrophy, and lymphocytic infiltrates with perivascular, perilobular, and periductal distribution.17

Regarding granulomatous mastitis, its pathophysiology has been linked to damage of the ductolobular system, favored by situations such as recent pregnancy, lactation, or hyperprolactinemia.2,3 Milk stasis can lead to extravasation of ductal contents into the breast parenchyma, which initially acts as a hidden antigen and later as a foreign body. This triggers an immune response mediated mainly by T lymphocytes and macrophages, culminating in the formation of the non-caseating granulomas characteristic of the disease.2,3 A pathogenic role has been proposed for Corynebacterium, mainly the Kroppenstedtii subtype, as a trigger or perpetrator of chronic inflammation.18–20 This opportunistic bacterium has slow growth (3-5 days) and great lipophilicity, requiring lipid-rich media for development. As these are not routine culture media, it is usually not detected in initial cultures, delaying diagnosis. Early request for these cultures reduces the probability of false negatives after antibiotic treatment.18–20 Also, since it is part of the normal skin flora, it is sometimes reported as a contaminant and disregarded.18–20

It has also been described as an autoimmune pathology due to its good response to corticosteroid therapy and pathological association with erythema nodosum and monoarthritis.2–5

Although there are multiple etiological differential diagnoses of mastitis, it is important to remember that the most clinically relevant differential diagnosis is inflammatory breast cancer, so its exclusion is a priority in the diagnostic approach.1–3,6,7

Case Reports

Two cases of premenopausal women with granulomatous mastitis are analyzed.

Case 1

A 40-year-old woman with obesity (BMI 36). Gynecological and obstetric history: 4 pregnancies, last one in 2021. Regular cycles. Hysterectomy for myomatosis.

On 09/15/25, she presented to the emergency department with a 6 cm indurated, painful mass in the right breast, associated with erythema, without fever.

A breast ultrasound was performed, reporting in the right breast: asymmetry in the lower-inner quadrant, with an area of increased echogenicity, vascularization, and laminar distribution edema of inflammatory appearance. There was also increased thickness of the cutaneous plane, consistent with the erythematous and indurated area. No collections. BIRADS 2.

With a diagnosis of non-abscessed nonspecific mastitis, empirical treatment was indicated with oral amoxicillin-clavulanic acid for 15 days, with poor clinical evolution.

On 10/02/25, a new breast ultrasound showed a right retroareolar abscess between the 3 and 6 o’clock positions, measuring 36x29 mm. Paraclinical tests revealed leukocytosis (10,440) and CRP of 37. Aspiration was performed for drainage and nonspecific culture. Hospital admission was decided, and intravenous treatment with trimethoprim-sulfamethoxazole was added, maintaining ampicillin-sulbactam.

After 5 days, there was a marked increase in fluctuating elements and fever. The culture showed no growth. A third ultrasound revealed a collected process occupying almost the entire right breast.

Surgical drainage was performed via periareolar incision, revealing an extensive cavity 8 cm in diameter, occupying the lower quadrants and retroareolar space, with abundant purulent content; washing and packing were performed. Samples were taken for bacteriological culture. Good evolution with trimethoprim-sulfamethoxazole and metronidazole; the patient was discharged. The culture showed no growth.

A new consultation was made 15 days later due to increased local pain (Figure 1). Ultrasound showed an abscess in the lower-inner quadrant of the right breast. ESR and CRP were normal.

Figure 1. Appearance of the right breast after surgical drainage in the operating room and following broad-spectrum antibiotic treatment.

Aspiration drainage was performed, with a third culture showing no bacterial growth. She received metronidazole 500 mg orally every 8 hours for 15 days, with good clinical evolution and resolution on ultrasound.

After discussion at a multidisciplinary meeting, a core needle biopsy was performed, concluding: sections of mammary parenchyma with fibrosis and marked mixed inflammatory infiltrate, with areas of abscess and multinucleated giant cells. Ducts lined by a double layer of cells, without cytoarchitectural atypia. No evidence of tuberculosis in cultures or biopsy. In summary: Chronic granulomatous mastitis with abscess formation. No evidence of malignancy.

Follow-up mammogram at one month showed no suspicious signs of malignancy. BIRADS 2. Evaluated jointly with a specialist in autoimmune diseases, prednisone 10 mg/day was started.

At one-month follow-up, erythema and edema persisted. Ultrasound showed no collections. Serology for syphilis negative, ESR and CRP normal. PPD and chest CT on 04/26/26 performed to rule out sarcoidosis and tuberculosis. Methotrexate 15 mg weekly was added, with good evolution on subsequent follow-up (Figure 2). She is currently in remission.

Figure 2. Clinical resolution after immunosuppressive treatment.

Clinical case 2

A 39-year-old woman with no relevant medical history. Menarche at age 15, regular cycles. Five pregnancies, breastfed for 2 years. Tubal ligation performed 4 years ago. Family history of ovarian cancer: maternal grandmother died at age 45, and maternal aunt at age 50.

She presented with right breast pain and a fistulized periareolar mass, with spontaneous suppuration and fluctuant areas in the outer quadrants (Figure 3A).

Figure 3. Side view of the right breast. Initial presentation and post-treatment evolution of case 2.

Mammography and ultrasound revealed a poorly defined heterogeneous mass with irregular borders, measuring 4 cm in diameter, located in the upper outer and retroareolar quadrant of the right breast. There was increased retroareolar density and thickening of the dermal and subdermal planes on the right nipple area. Bilateral axillary lymph nodes were observed. BIRADS 4a. (Figure 4).

Figure 4. Initial mammogram showing a 4 cm heterogeneous mass with irregular borders in the upper outer and retroareolar quadrant of the right breast. BIRADS 4a.

bacteriological cultures of the purulent secretion showed no growth. A biopsy of the skin and lesion was performed with drainage of the collection. Pathology reported chronic mastitis with microabscess foci, with no evidence of malignancy.

The case was discussed at a multidisciplinary committee with the rheumatology team, and a diagnosis of granulomatous mastitis was suggested. Corticosteroid therapy was started with dexamethasone 4 mg daily, followed by gradual tapering.

Initially, there was poor clinical evolution, so a breast MRI was performed, revealing a suspicious mass-like enhancement, with skin and pectoral muscle edema. BIRADS 4B. A new core biopsy reported an active chronic inflammatory process with microabscesses, with no evidence of malignancy.

Meanwhile, differential diagnoses were investigated: neoplastic processes, tuberculosis, sarcoidosis, foreign body reaction, fungal infections, duct ectasia, histoplasmosis, and even systemic diseases such as granulomatosis with polyangiitis, giant cell arteritis, or polyarteritis nodosa. For this, a PPD test, Ziehl-Neelsen staining, and a chest X-ray were performed, all of which were normal. The latter also did not show the hilar lymphadenopathy present in 90% of sarcoidosis cases. PR3, MPO, and ANA were also performed to rule out ANCA-positive vasculitis. VDRL testing ruled out syphilitic etiology.

Mycological studies of the purulent content were negative, ruling out fungal infections. With these diagnoses excluded, the primary diagnosis was granulomatous mastitis with poor response to corticosteroid therapy, so azathioprine 150 mg/day was started.

Monthly clinical, imaging, and laboratory follow-ups were performed (Figure 3B-C). These showed a slight increase in ESR and CRP, without leukocytosis or dysfunction.

There was a slow but good clinical and imaging improvement, with a slight decrease in complement levels, so methotrexate 15 mg weekly and folic acid were added.

Ultrasound and mammography follow-ups were BIRADS 2, with marked clinical improvement and laboratory results within normal range, so corticosteroid therapy was gradually tapered and then definitively discontinued four years after onset. To date, a year and a half after completing treatment, there has been no recurrence (Figure 3D).

Discussion

Granulomatous mastitis is usually a diagnosis of exclusion. Due to its prognostic importance, inflammatory breast cancer must be ruled out by imaging and biopsy.1–3 Among the differential diagnoses for its etiology are: tuberculous mastitis, histoplasmosis and Mycobacterium avium in immunocompromised patients, periductal mastitis with duct ectasia, and autoimmune diseases such as Wegener’s granulomatosis or breast sarcoidosis.2–5

In both cases, the clinical presentation was characterized by pain and inflammatory signs over a unilateral breast mass, progressing to abscess formation and fistulous tracts, consistent with what has been described in the literature. As a result, biopsies were essential to rule out malignancy, and other infectious causes were subsequently excluded.1,2,6,7

Imaging studies have low specificity for diagnosis. Mammography may reveal increased breast density with focal asymmetry or an irregular mass.1–3 Ultrasound usually shows an irregular hypoechoic image with posterior shadowing, or the presence of tubular areas and thickening of tissue planes. It allows for the diagnosis of breast abscess, as well as guiding aspiration and biopsy procedures.1–3

Breast MRI visualizes heterogeneous lesions with central hypointensity and peripheral hyperintensity. Although it does not increase diagnostic yield, in some cases it may help assess the extent and evolution of the disease or rule out other differential diagnoses for mastitis.2,3

As seen in the second clinical case, imaging continued to raise suspicion of malignancy due to mammographic and ultrasound findings classified as BI-RADS 4A, and later, magnetic resonance imaging as BI-RADS 4B.

Histological analysis is fundamental, as it rules out breast cancer—the main and most important suspicion in this clinical context.1–3

Histologically, granulomatous mastitis presents with non-caseating granulomas composed of multinucleated giant cells, limited to the breast lobules with microabscesses.1–3 In the case mentioned, a repeat biopsy demonstrated an active inflammatory process consistent with granulomatous mastitis and showed no evidence of malignancy.

These findings are consistent with what has been described for this disease and reaffirm that the diagnosis does not depend exclusively on imaging characteristics. Both cases demonstrated the wide variability of imaging findings according to the evolutionary stage of the disease and their low specificity, with imaging being mainly useful for determining the extent of the disease, the presence of collections, and for guiding procedures.1–3

Microbiology represents another important but controversial aspect of granulomatous mastitis. In both patients, bacteriological cultures showed no growth of microorganisms. The suggested association with Corynebacterium could not be evaluated due to the absence of optimal cultures for its detection. In this context, the negative cultures observed in our cases do not allow us to confirm or exclude an infectious component.

The absence of bacterial growth in both cases also contributed to the fact that the definitive diagnosis relied mainly on histopathological evaluation and the exclusion of other etiologies.

Williams et al., in their retrospective study analyzing 35 samples from 22 patients using optimal culture media, identified Presumptive Corynebacterium spp. as the main pathogens, followed by Corynebacterium spp. and Propionibacterium acnes (now Cutibacterium acnes).24

Tape et al., in their retrospective study of 165 patients, highlighted the presence of Corynebacterium in 15.15% of cases and associated it with greater severity and extent of abscesses, as well as the need for surgical drainage. Although optimal cultures were not possible in the first case, greater disease extension, abscess formation, and recurrence were observed, comparable to what the author described in their study.25

Despite its self-limited course, granulomatous mastitis may last from 6 months to 2 years. Treatment is necessary due to the marked symptoms, and its functional and aesthetic repercussions.2–5

Treatment is not fully standardized and achieves its best results within a multidisciplinary and multimodal framework. Three fundamental pillars are described:

Antibiotic therapy, with initial use of lipophilic antibiotics such as doxycycline 100 mg every 12 hours, adjusted according to culture results.18–20 Dobinson et al. support this information. They highlight that, due to the characteristics of Corynebacterium kroppenstedtii, there may be resistance to β-lactam antibiotics, and the use of lipophilic antibiotics achieves better results.26

Corticosteroid therapy has been described orally, topically, or intralesionally. Multiple studies have evaluated its utility both alone and in combination; however, there is still no consensus.3–5,21

Oral administration involves prednisone 30-40 mg/day, with early reduction to 20 mg/day. Continue for 4 to 6 months with gradual tapering to avoid complications.3,4,22

Topical use involves prednisolone 0.125%: twice daily on alternate days. It has similar efficacy with a lower incidence of adverse effects.3,4,2

Ultrasound-guided intralesional infiltration with triamcinolone acetonide has been described. Although studies include small populations, its efficacy and fewer adverse effects are noteworthy. On the other hand, the doses and duration are not standardized, varying from 20 mg to 40 mg per session.4,5

Immunosuppressants act as steroid-sparing agents; methotrexate is used at a dose of 15 mg weekly combined with folic acid.3,4

Tekgöz E et al., in their retrospective study of 51 patients who received immunosuppressive treatment, reported that 98% achieved complete remission.27 This is consistent with a recent systematic review and meta-analysis involving nine studies, which found a 61.6% response rate to methotrexate.

Therefore, recent evidence positions methotrexate as an effective and generally well-tolerated therapeutic alternative, although published response rates show considerable heterogeneity and do not allow it to be established as a universal treatment.28

Surgical treatment is not recommended and should be reserved only for extensive disease and therapeutic failure.2–5

Along these lines, in Case 1, the process was initially interpreted as infectious, leading to antibiotic therapy and drainage of extensive collections. This treatment was ineffective, with subsequent recurrence and persistence of the inflammatory component, demonstrating that abscess control did not resolve the underlying granulomatous process. Prednisone was subsequently added, but inflammatory signs persisted. The introduction of methotrexate led to a favorable course and clinical remission. This behavior is consistent with the use of immunosuppressants as an effective and steroid-sparing strategy in patients with insufficient response or persistent disease.

Similarly, the second case also showed an insufficient response to initial corticosteroid treatment. Azathioprine was introduced, followed by methotrexate, resulting in gradual clinical and imaging improvement. The need to modify and escalate treatment during the course of the disease is consistent with published experience, where the response may be variable, and relapses or persistence of the disease may require prolonged treatments. In this patient, it was also possible to progressively reduce corticosteroids until their complete discontinuation, with no recurrence during subsequent follow-up.

As discussed, we can confirm that both cases are consistent with what has been described in the literature: unilateral involvement, prolonged inflammatory course, abscess and fistula formation, negative cultures, difficulty excluding malignancy, and the need for individualized treatment. At the same time, they show differences in clinical evolution and therapeutic response, highlighting the heterogeneity of this disease and the need for a multidisciplinary and individualized approach. While one patient had a predominantly abscessed evolution requiring drainage and later immunosuppressive treatment, the other presented with persistent disease and imaging findings more suggestive of malignancy, requiring a prolonged immunosuppressive strategy. Follow-up should be long-term with rheumatology or dermatology, and the recurrence rate is high.2–5

Conclusions

Granulomatous mastitis is a rare entity with limited scientific evidence regarding its etiopathogenesis. Awareness and clinical suspicion in diagnosis will help avoid delays in treatment and optimize management.

We propose an initial management protocol for non-puerperal mastitis, involving early requests for cultures that include specific strains in lipophilic media, as well as early tissue sampling. This allows for targeted treatment, reducing its chronic and recurrent course and possible aesthetic sequelae.

Declarations

Ethics
The patients included in the study provided written informed consent for the use of their clinical data for scientific purposes and for the publication of the results. Confidentiality and anonymity of the information were preserved at all times.

References

  1. Sociedad de Patología Mamaria de Córdoba. Mastitis granulomatosa. In: Reunión científica [Internet]. Córdoba, Argentina: Sociedad de Patología Mamaria de Córdoba; 2025. Accessed March 24, 2026. https://spmcba.com.ar/reunion-cientifica/
  2. Vilela Desposorio C, Lozada Cáceda JA. Mastitis granulomatosa no caseificante: revisión retrospectiva de 61 casos. Rev Senol Patol Mamar. 2024;37(1):100546. doi:10.1016/j.senol.2023.100546
  3. Dilaveri C, Degnim AC, Lee CN, DeSimone DC, Moldoveanu D, Ghosh K. Idiopathic granulomatous mastitis. Breast J. 2024;2024:6693720. doi:10.1155/2024/6693720
  4. Vercoe J, Sedaghat N, Brennan ME. Intralesional steroid injections for management of granulomatous mastitis: a systematic review of treatment protocols and clinical outcomes. Breast J. 2025;2025:2592366. doi:10.1155/tbj/2592366.
  5. Moldoveanu D, Lee C, Hesley G. Framework and guide for intralesional steroid injections in idiopathic granulomatous mastitis. Eur J Radiol. 2023;168:111118. doi:10.1016/j.ejrad.2023.111118.
  6. Bonilla Sepúlveda ÓA, Calvo Herrera DE. Mastitis granulomatosa. Medicina UPB. 2020;39(2):41–48. DOI: 10.18566/medupb.v39n2.a07.
  7. Jiménez González M, Melero López A, Sánchez Gabaldón R. Mastitis granulomatosa. Clínica e Investigación en Ginecología y Obstetricia. 2015;42(3):141-144. doi:10.1016/j.gine.2014.02.001.
  8. Khanal S, Kafle A, Bhandari S, Kayastha P. A rare extrapulmonary presentation of tuberculosis: breast tuberculosis. Clin Case Rep. 2023;11(7). doi:10.1002/ccr3.7728
  9. Vita S, Piccolo C, Maffongelli G, et al. Tuberculous mastitis, the great imitator in breast disease: a case report with diagnostic and therapeutic challenges. Infect Dis Poverty. 2026;15:7. doi:10.1186/s40249-025-01391-9
  10. Zhou MM, Geng L. Secondary syphilis with acute mastitis as the initial manifestation. J Eur Acad Dermatol Venereol. 2025;39(12):2142. doi:10.1111/jdv.20592.
  11. Duran M, Campos-Murguia A, Ocampo-Candiani J. Primary syphilis of the nipple: a rare presentation of a common disease. Dermatol Online J. 2020;26(2). doi:10.5070/D3262047444
  12. Plachouri KM, Mulita F, Oikonomou C, Papadopoulou M. Nipple candidiasis and painful lactation: an updated overview. Adv Dermatol Allergol. 2022;39(4):651-655. doi:10.5114/ada.2022.116837
  13. Douglas P. Overdiagnosis and overtreatment of nipple and breast candidiasis: a review of the relationship between diagnoses of mammary candidiasis and Candida albicans in breastfeeding women. Womens Health (Lond).2021;17:17455065211031480. doi:10.1177/17455065211031480
  14. Oliveira VCM, Cubas-Vega N, López Del-Tejo P, et al. Non-lactational infectious mastitis in the Americas: a systematic review. Front Med (Lausanne). 2021;8:672513. doi:10.3389/fmed.2021.672513
  15. Cansado P, Merck B, Fernández-Frías A, Lacueva FJ, Navarro JM, Calpena R. Enfermedad inflamatoria mamaria asociada con los conductos. Rev Senol Patol Mam. 2006;19(4):183-185.
  16. D’Alfonso TM, Ginter PS, Shin SJ. A review of inflammatory processes of the breast with a focus on diagnosis in core biopsy samples. J Pathol Transl Med. 2015;49(4):279–287. DOI: 10.4132/jptm.2015.06.11.
  17. Guzik P, Gęca T, Topolewski P, Harpula M, Pirowski W, Koziełek K, et al. Diabetic mastopathy: review of diagnostic methods and therapeutic options. Int J Environ Res Public Health. 2022;19(1):448. doi:10.3390/ijerph19010448.
  18. Tauch A, Fernández-Natal I, Soriano F. A microbiological and clinical review of Corynebacterium kroppenstedtii. Int J Infect Dis. 2016;48:33-39. doi:10.1016/j.ijid.2016.04.023
  19. Taylor GB, Paviour SD, Musaad S, Jones WO, Holland DJ. A clinicopathological review of 34 cases of inflammatory breast disease showing Corynebacterium kroppenstedtii. Pathology. 2003;35(2):109-119.
  20. Paviour SD, Musaad SA, Roberts SA, Taylor GJ, Taylor SL, Shore KP, et al. Corynebacterium species isolated from patients with mastitis. Clin Infect Dis. 2002;35(11):1434-1440. DOI: 10.1086/344463
  21. Zhang Q, Zhang W, Lv J, Zhang Z, Zhao Y. The effect of local steroid administration on idiopathic granulomatous mastitis: a systematic review and meta-analysis. J Surg Res. 2024;295:511-521. doi:10.1016/j.jss.2023.11.024.
  22. Wolfrum A, Kümmel S, Theuerkauf I, Pelz E, Reinisch M. Granulomatous mastitis: a therapeutic and diagnostic challenge. Breast Care (Basel). 2018;13(6):413-418. doi:10.1159/000495146.
  23. Altintoprak F, Kivilcim T, Yalkin O, Uzunoglu Y, Kahyaoglu Z, Dilek ON. Topical steroids are effective in the treatment of idiopathic granulomatous mastitis. World J Surg. 2015;39(11):2718–2723. doi:10.1007/s00268-015-3147-9
  24. Williams MS, McClintock AH, Bourassa L, Laya MB. Treatment of granulomatous mastitis: is there a role for antibiotics? Eur J Breast Health. 2021;17(3):239-246. doi:10.4274/ejbh.galenos.2021.2021-3-1.
  25. Tepe D, Uluşahin M, Kul S, Yılmaz G. Corynebacterium in granulomatous mastitis: clinical features and treatment outcomes. Infect Dis Clin Microbiol. 2026;8(4):339-350. doi:10.36519/idcm.2026.1044.
  26. Dobinson HC, Anderson TP, Chambers ST, Doogue MP, Seaward L, Werno AM. Antimicrobial treatment options for granulomatous mastitis caused by Corynebacterium species. J Clin Microbiol. 2015;53(9):2895-2899. doi:10.1128/JCM.00760-15
  27. Tekgöz E, Çolak S, Çinar M, Yilmaz S. Treatment of idiopathic granulomatous mastitis and factors related with disease recurrence. Turk J Med Sci. 2020;50(5):1380-1386. doi:10.3906/sag-2003-93.
  28. Han Y, Shi L, Zhang Y. Efficacy and tolerability of methotrexate for idiopathic granulomatous mastitis: a systematic review and meta-analysis. Breast J. 2026;2026:6710172. doi:10.1155/tbj/6710172

Article information

Authors

How to cite

Gutiérrez, A., Cerchiari, E., et al., 2026. Granulomatous mastitis: a disease with heterogeneous presentation and complex management. Case series and literature review.. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0619

Record

Journal
Medical Research Archives
Section
Case Reports
Published
31 October 2026
ISSN
2375-1924
Downloads
60

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.